Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046526 · ClinicalTrials.gov registry record
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 100
- Enrollment target
NCT01046526: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01046526 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046526 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Background: * Individuals who have schizophrenia are significantly more likely to smoke than the general population, which leads to increased smoking-related illnesses and high rates of nicotine dependence. Research suggests that high rates of smoking and nicotine addiction in people with schizophrenia are related to the fact that nicotine temporally improves performance in several cognitive tasks, including sensory gating, long-term memory, and visual tracking-all of which are affected by schizophrenia. * Smoking among schizophrenia patients may be a form of self-medication, since nicotine may temporarily treat and improve cognitive deficits caused by schizophrenia. Researchers are interested in studying the effects of nicotine on the brain activity of individuals with schizophrenia to better understand how nicotine affects the brain regions connected to memory, visual tracking, and attention. Objectives: * To identify specific brain regions involved in the anticipatory learning deficits found in schizophrenia patients who smoke. * To determine whether and how nicotine enhances performance in these regions. Eligibility: \- Smokers (at least 10 cigarettes per day) between 18 and 50 years of age who either are healthy volunteers or have been diagnosed with schizophrenia/schizoaffective disorder. Design: * Participants will be asked to avoid consuming alcohol and restrict consuming caffeinated beverages for 24 hours before the study days. Participants will provide urine and breath samples at the start of the study to be tested for chemicals that may interfere with the study. * The study will require two to four visits, with two fMRI sessions and other visits for a clinical interview or training. Participants will have a training session with a possible mock MRI scan to learn how to do tasks that track eye movement and measure ability to pay attention. * During the fMRI scanning sessions, participants will receive either a nicotine patch or a placebo patch wit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-02-08 |
| Est. Completion | 2012-05-03 |
What the finished NCT01046526 record still lists
NCT01046526 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01046526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01046526 about?
NCT01046526 is a clinical study titled "fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia". Background: * Individuals who have schizophrenia are significantly more likely to smoke than the general population, which leads to increased smoking-related illnesses and high rates of nicotine dependence. Research suggests that high rates of smoking and nicotine addiction in people with schizophr...
What is the current status of trial NCT01046526?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2005-02-08. Estimated completion is 2012-05-03.
Who is sponsoring clinical trial NCT01046526?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI